Bernardo Amisa Panka1, Harm-Jan de Grooth, Angélique Maria Elisabeth Spoelstra-de Man, Mark R Looney, Pieter-Roel Tuinman. 1. *Department of Intensive Care Medicine, VU University Medical Centre, Amsterdam, The Netherlands †Department of Intensive Care Medicine, s' Lands Hospitaal Paramaribo, Paramaribo, Suriname ‡Research VUmc Intensive Care (REVIVE) and Institute for Cardiovascular Research (ICAR-VU), Amsterdam, The Netherlands §Department of Medicine, University of California, San Francisco; San Francisco, California.
Abstract
BACKGROUND: The acute respiratory distress syndrome (ARDS) is a life-threating disorder that contributes significantly to critical illness. No specific pharmacological interventions directed at lung injury itself have proven effective in improving outcome of patients with ARDS. Platelet activation was identified as a key component in ARDS pathophysiology and may provide an opportunity for preventive and therapeutic strategies. We hypothesize that use of acetyl salicylic acid (ASA) may prevent and/or attenuate lung injury. METHODS: We conducted a systematic review of preclinical studies and meta-analysis of clinical studies investigating the efficacy of ASA in the setting of lung injury. Medline, embase, and cochrane databases were searched. RESULTS: The literature search yielded 1,314 unique articles. Fifteen preclinical studies and eight clinical studies fulfilled the in- and exclusion criteria. In the animal studies, the overall effect of ASA was positive, e.g., ASA improved survival and attenuated inflammation and pulmonary edema. Mechanisms of actions involved, among others, are interference with the neutrophil-platelets interaction, reduction of leukotrienes, neutrophil extracellular traps, and prostaglandins. High-dose ASA may be the drug of choice. A meta-analysis of three clinical studies showed an association between ASA use and a reduced incidence of ARDS (OR 0.59, 95% CI 0.36-0.98), albeit with substantial between-study heterogeneity. All studies had their own shortcomings in methodological quality. CONCLUSION: This systematic review of preclinical studies and meta-analysis of clinical studies suggests a beneficial role for ASA in ARDS prevention and treatment. However, the currently available data is insufficient to justify an indication for ASA in ARDS. The body of literature does support further studies in humans. We suggest clinical trials in which the mechanisms of action of ASA in lung injury models are being evaluated to guide optimal timing and dose, before prospective randomized trials.
BACKGROUND: The acute respiratory distress syndrome (ARDS) is a life-threating disorder that contributes significantly to critical illness. No specific pharmacological interventions directed at lung injury itself have proven effective in improving outcome of patients with ARDS. Platelet activation was identified as a key component in ARDS pathophysiology and may provide an opportunity for preventive and therapeutic strategies. We hypothesize that use of acetyl salicylic acid (ASA) may prevent and/or attenuate lung injury. METHODS: We conducted a systematic review of preclinical studies and meta-analysis of clinical studies investigating the efficacy of ASA in the setting of lung injury. Medline, embase, and cochrane databases were searched. RESULTS: The literature search yielded 1,314 unique articles. Fifteen preclinical studies and eight clinical studies fulfilled the in- and exclusion criteria. In the animal studies, the overall effect of ASA was positive, e.g., ASA improved survival and attenuated inflammation and pulmonary edema. Mechanisms of actions involved, among others, are interference with the neutrophil-platelets interaction, reduction of leukotrienes, neutrophil extracellular traps, and prostaglandins. High-dose ASA may be the drug of choice. A meta-analysis of three clinical studies showed an association between ASA use and a reduced incidence of ARDS (OR 0.59, 95% CI 0.36-0.98), albeit with substantial between-study heterogeneity. All studies had their own shortcomings in methodological quality. CONCLUSION: This systematic review of preclinical studies and meta-analysis of clinical studies suggests a beneficial role for ASA in ARDS prevention and treatment. However, the currently available data is insufficient to justify an indication for ASA in ARDS. The body of literature does support further studies in humans. We suggest clinical trials in which the mechanisms of action of ASA in lung injury models are being evaluated to guide optimal timing and dose, before prospective randomized trials.
Authors: Jochen Grommes; Jean-Eric Alard; Maik Drechsler; Sarawuth Wantha; Matthias Mörgelin; Wolfgang M Kuebler; Michael Jacobs; Philipp von Hundelshausen; Philipp Markart; Malgorzata Wygrecka; Klaus T Preissner; Tilman M Hackeng; Rory R Koenen; Christian Weber; Oliver Soehnlein Journal: Am J Respir Crit Care Med Date: 2012-01-12 Impact factor: 21.405
Authors: Axelle Caudrillier; Kai Kessenbrock; Brian M Gilliss; John X Nguyen; Marisa B Marques; Marc Monestier; Pearl Toy; Zena Werb; Mark R Looney Journal: J Clin Invest Date: 2012-06-11 Impact factor: 14.808
Authors: Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Driss El Kebir; Levente József; Wanling Pan; Lili Wang; Nicos A Petasis; Charles N Serhan; János G Filep Journal: Am J Respir Crit Care Med Date: 2009-05-29 Impact factor: 21.405
Authors: Jeffrey N Harr; Ernest E Moore; Jeffrey Johnson; Theresa L Chin; Max V Wohlauer; Ronald Maier; Joseph Cuschieri; Jason Sperry; Anirban Banerjee; Christopher C Silliman; Angela Sauaia Journal: Crit Care Med Date: 2013-02 Impact factor: 7.598
Authors: Carlijn R Hooijmans; Maroeska M Rovers; Rob B M de Vries; Marlies Leenaars; Merel Ritskes-Hoitinga; Miranda W Langendam Journal: BMC Med Res Methodol Date: 2014-03-26 Impact factor: 4.615
Authors: George Kasotakis; Manuel D Galvan; Paw Osathanugrah; Neerav Dharia; Lauren Bufe; Zachary Breed; Joseph P Mizgerd; Daniel G Remick Journal: J Surg Res Date: 2017-07-31 Impact factor: 2.192
Authors: Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman Journal: Am J Respir Cell Mol Biol Date: 2018-07 Impact factor: 6.914
Authors: Tatyana A Kuznetsova; Boris G Andryukov; Ilona D Makarenkova; Tatyana S Zaporozhets; Natalya N Besednova; Ludmila N Fedyanina; Sergey P Kryzhanovsky; Mikhail Yu Shchelkanov Journal: Molecules Date: 2021-04-29 Impact factor: 4.411
Authors: Siân Lax; Julie Rayes; Surasak Wichaiyo; Elizabeth J Haining; Kate Lowe; Beata Grygielska; Ryan Laloo; Per Flodby; Zea Borok; Edward D Crandall; David R Thickett; Steve P Watson Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-08-24 Impact factor: 5.464